Clioquin 0.025%+3%3 gm

Clioquin 0.025%+3% is a topical combination product indicated for the short-term treatment of inflammatory skin conditions that have, or are suspected to have, a bacterial and/or fungal component.

Established uses

• Infected or suspected-infected eczema and dermatitis with a bacterial and/or fungal component
• Intertrigo (skin-fold rash) with associated bacterial/fungal infection
• Other inflammatory dermatoses (e.g., infected contact dermatitis, infected seborrhoeic dermatitis) where a corticosteroid is indicated for inflammation and a topical antibacterial/antifungal is indicated for accompanying infection

Important note

Clioquin 0.025%+3% is intended for short-term use to bring the inflammatory and infective components of the condition under control; it is not intended as a long-term or maintenance therapy. It should not be used to treat skin infections that have no inflammatory component, or inflammation with no suspected infective component, since unnecessary corticosteroid or antimicrobial exposure should be avoided.

Each unit (cream/ointment, as per the specific formulation) of Clioquinol + Fluocinolone Acetonide contains:

• Clioquinol (iodochlorhydroxyquin) - a halogenated hydroxyquinoline derivative with topical antibacterial and antifungal activity
• Fluocinolone Acetonide - a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive activity

Exact strengths vary by brand and formulation; refer to the specific product label for precise composition.

Clioquin 0.025%+3% is a fixed-dose topical combination formulated for local application to inflamed skin conditions with a suspected or confirmed bacterial or fungal component. It combines two complementary actions:

• Clioquinol provides local antibacterial and antifungal coverage against common skin pathogens by chelating trace metal ions essential to microbial growth.
• Fluocinolone acetonide is a mid-potency topical corticosteroid that reduces local inflammation, redness, swelling, and itching.

Clioquin 0.025%+3% is intended for short-term topical use only, as directed by a physician, and should be discontinued once the infective and inflammatory components are controlled.

Clioquin 0.025%+3% belongs to the therapeutic class of topical corticosteroid-antimicrobial combination preparations, combining a hydroxyquinoline antibacterial/antifungal agent with a synthetic corticosteroid.

Clioquinol + Fluocinolone Acetonide exerts its therapeutic effect through the combined pharmacological actions of its two components.

Clioquinol

A hydroxyquinoline derivative that exerts antibacterial and antifungal activity, largely attributed to chelation of metal ions (e.g., iron, copper) required for microbial enzymatic function, thereby inhibiting the growth of a range of gram-positive bacteria, dermatophytes, and yeasts (e.g., Candida species) on the skin surface.

Fluocinolone acetonide

A synthetic corticosteroid that binds intracellular glucocorticoid receptors, inducing anti-inflammatory proteins and suppressing pro-inflammatory mediators (e.g., prostaglandins, leukotrienes, cytokines). This reduces local vasodilation, capillary permeability, inflammatory cell infiltration, and pruritus at the site of application.

Clioquin 0.025%+3% is for external topical use only. Gently clean and dry the affected area before application. Apply a thin film and rub in gently; wash hands after application unless the hands are the treated area. Do not apply under occlusive dressings or airtight coverings (including tight nappies/diapers in infants) unless specifically directed by a physician, as this increases systemic absorption. Avoid contact with the eyes, mouth, and mucous membranes. Not for oral, ophthalmic, or intravaginal use.

Well-verified, clinically significant drug interactions with Clioquin 0.025%+3% are limited given its topical route of administration and generally low systemic absorption when used as directed over limited areas and duration.

• Other topical corticosteroids or antimicrobials: Concurrent application of other topical steroid or antimicrobial products to the same area may increase the risk of local irritation, sensitization, or excessive corticosteroid exposure; avoid combining without medical advice.
• Thyroid function tests: Because clioquinol contains iodine, its topical absorption can interfere with certain thyroid function tests (e.g., protein-bound iodine, radioactive iodine uptake), producing spuriously abnormal results; inform your physician or laboratory of recent use.
• Other systemically absorbed corticosteroids: Concomitant use of other corticosteroids (topical, inhaled, or systemic) may add to the overall corticosteroid burden if extensive body surface area is treated; use with caution.

Inform your physician or pharmacist of all other medicines, including topical products, that you are using.

Side effects with Clioquin 0.025%+3% are usually local and mild when used as directed, but may include:

• Local burning, stinging, or itching sensation at the application site
• Local skin irritation, dryness, or contact dermatitis/hypersensitivity reaction
• Yellow-brown staining of the skin, hair, and fabrics - a recognized cosmetic effect of clioquinol that patients should be counselled about

Less common, generally associated with prolonged or excessive use of the corticosteroid component:

• Local skin thinning (atrophy), striae, telangiectasia, and hypopigmentation, particularly on the face, skin folds, or under occlusion - see Precautions and Warnings
• Masking or worsening of untreated infection
• Rarely, with extensive or prolonged use over large body surface areas, systemic absorption of clioquinol has historically been associated with neurological effects (subacute myelo-optic neuropathy, SMON), a risk described mainly with oral/high-dose exposure; topical use at labeled doses and areas carries a much lower risk - see Precautions and Warnings

Discontinue use and consult a physician if a severe or persistent reaction occurs.

Data on the use of Clioquin 0.025%+3% during pregnancy and lactation are limited. As with other topical corticosteroid-containing combinations, this product should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; avoid use over large areas or for prolonged periods. Use during breastfeeding should be under medical supervision, and application to the breast/nipple area should be avoided if breastfeeding, to prevent inadvertent ingestion by the infant. Consult a physician before use if pregnant, planning pregnancy, or breastfeeding.

Observe the following precautions when using Clioquin 0.025%+3%:

• For external topical use only; not for oral, ophthalmic, or intravaginal use
• Use for the shortest effective duration; prolonged use of the corticosteroid component, particularly on the face, skin folds, or under occlusion, can cause local skin thinning, striae, telangiectasia, and other steroid-related skin changes
• Avoid application to extensive body surface areas or use under occlusive dressings, as this increases systemic absorption of both components
• Clioquin 0.025%+3% may cause yellow-brown staining of skin, hair, and clothing; counsel patients about this cosmetic effect before use
• Because clioquinol is an iodinated compound, avoid use in patients with known iodine sensitivity, and be aware that topical absorption may interfere with thyroid function tests
• Avoid extensive body surface area use or prolonged treatment in children without direct medical guidance, given both the corticosteroid and clioquinol absorption considerations
• Discontinue use and seek medical advice if irritation worsens, sensitization develops, or the treated infection fails to improve
• Avoid contact with the eyes; if accidental contact occurs, rinse thoroughly with water

Topical overdose or accidental ingestion of Clioquin 0.025%+3% is unlikely with correct use over limited areas and short durations, but excessive, extensive, or prolonged use may increase the risk of systemic corticosteroid effects (e.g., adrenal suppression) or clioquinol-related systemic effects (e.g., rare neurological effects with extensive/prolonged exposure). In case of suspected overdose or accidental ingestion, seek immediate medical attention or contact a poison control center; do not attempt specific home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly: No specific dose adjustment is generally required for Clioquin 0.025%+3% in elderly patients, but their skin is often thinner and more susceptible to corticosteroid-related atrophy; use with caution and monitor for local skin changes.

Renal/hepatic impairment: No well-established dose adjustment is required for topical use, as systemic absorption is minimal when used as directed; however, caution is advised with prolonged or extensive application.

Pediatric patients: See Pediatric Uses.

Pregnancy/lactation: See Pregnancy and Lactation.

Use of Clioquin 0.025%+3% should generally be limited to short-term treatment, commonly up to 1-2 weeks, unless otherwise directed by a physician. Prolonged use beyond the labeled period increases the risk of local corticosteroid-related side effects and clioquinol-related systemic absorption. If the treated condition does not improve within this period, or worsens, consult a physician for re-evaluation.

Clioquinol + Fluocinolone Acetonide is classified as a topical corticosteroid-antimicrobial combination product comprising a hydroxyquinoline antibacterial/antifungal agent (clioquinol) and a synthetic corticosteroid (fluocinolone acetonide).

Clioquinol + Fluocinolone Acetonide acts through two complementary mechanisms: clioquinol chelates metal ions essential to bacterial and fungal growth, providing local antimicrobial activity, while fluocinolone acetonide binds glucocorticoid receptors to suppress local inflammatory mediators, reducing redness, swelling, and itching.

Safety and efficacy of Clioquin 0.025%+3% in pediatric patients, particularly infants, have not been well established. Children have a higher ratio of skin surface area to body weight than adults, which increases the risk of systemic absorption of both the corticosteroid and clioquinol components. Use in children should only be under the direct supervision of a physician, with the smallest effective amount, the shortest possible duration, and avoidance of occlusive dressings (including tight-fitting diapers/nappies) or use over extensive areas.